Leukocare has opened development laboratories and offices in Milford, Massachusetts, USA.
The location will enable Leukocare to collaborate closely with customers and partners in the field of drug product formulation development for biopharmaceuticals and advanced therapy medicinal products (ATMP). An in-house biostatistics team will work with algorithms and deep learning to provide individually designed solutions for clients.
The US offices and laboratories are located at Rentschler Biopharma´s Milford premises. The two companies have shared a global strategic alliance since 2017 to offer integrated formulation development services at every step of the biopharmaceutical value chain.
Michael Scholl, CEO at Leukocare, said: “I am delighted to announce the opening of Leukocare´s US site today. The company´s outstanding development over the last few years led to our desire of establishing a presence in the largest pharmaceuticals market worldwide. This strategic step enables us to be even closer to both our US and global customers and to better understand and serve their needs.
“Furthermore, the existing infrastructure of Rentschler in Milford – that we will partially make use of – allows us to start operations without any delay and thus makes Milford the perfect choice for our newly established US site. We therefore will continue to pursue our strategy of pushing boundaries of biopharmaceutical product development by combining innovative biostatistics, artificial intelligence and vast formulation expertise with first-class analytics.”